Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + Gemcitabine in Advanced Biliary Tract Cancer
NCT02425137Phase 2Completed
- Sponsor
- TTY Biopharm Company Limited
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in biliary tract cancer (BTC), sponsored by TTY Biopharm Company Limited. Primary endpoint: Disease Control Rate at 2 years. Started Apr 2015; status: completed.
02
Drugs
tegafur
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02425137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425137.